CD19-Targeting in Relapsed/Refractory DLBCL: Optimizing the Use of Noncellular Therapies

Did you know that noncellular CD19-targeted therapies represent a new therapeutic option in both transplant eligible and ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)? Credit available for this activity expires: 10/18/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/997427?ecd=bdc_podcast_libsyn_mscpedu